U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT06962098) titled 'Efficacy and Safety Study of Isuzinaxib in Subjects With DKD' on April 16.
Brief Summary: This study is a multicenter, double-blinded, randomized, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PK, and efficacy of Isuzinaxib compared with placebo in subjects with DKD.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Diabetic Kidney Disease (DKD)
Intervention:
DRUG: Isuzinaxib
Oral dosing regimen once daily
DRUG: Placebo
Oral dosing regimen once daily
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Aptabio Therapeutics, Inc.
Published by HT Digital Content Services with permissio...